Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Double-blind, Randomized, Parallel Group, 4-week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of Pf-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control

Next Previous
Trial Profile

A Phase 2, Multicenter, Double-blind, Randomized, Parallel Group, 4-week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of Pf-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mardepodect (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 01 Nov 2019 Primary endpoint (Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4) has not been met as per the result published in the Journal of Clinical Psychopharmacology
  • 01 Nov 2019 Results assessing Efficacy and safety of PF-02545920 Compared To Placebo in patients with Acute Exacerbation Of Schizophrenia published in the Journal of Clinical Psychopharmacology
  • 10 Apr 2012 Actual patient number is 259 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top